The Vaccines Market Outlook: Market analysis of future growth and leading players by sector

Table of Contents

Executive summary

Introduction to vaccines & vaccine-preventable diseases

Vaccines market analysis

Pediatric vaccines

Adult vaccines

Key players in the vaccines market

Sources and limitations of vaccine sales data

Chapter 1 Introduction to vaccines &

vaccine-preventable diseases

Summary

Introduction

History of vaccines

Vaccines and the immune system

The immune system

Immunity by vaccination

Types of vaccines

Problems with vaccine development

DNA vaccines

Vaccine-preventable diseases

Measles

Mumps

Rubella

Diphtheria

Tetanus

Pertussis

Meningitis (pneumococcus, meningococcus and Hib)

Varicella

Hepatitis B

Influenza

Typhoid

Rabies

Chapter 2 Vaccines market analysis

Summary

Introduction

Vaccines as part of the infectious diseases market

Vaccine market segments

Leading vaccine brands

Key players in the vaccines market

Future growth drivers

Chapter 3 Pediatric vaccines

Summary

Introduction

Pediatric immunization schedule

Government recommendations

Immunization funding

US

Europe

Measles/Mumps/Rubella (MMR) vaccines

Brand market share and sales

Brand analysis

MMR II

Priorix

Diphtheria/Tetanus/Pertussis (DTP) vaccines

Brand market share and sales

Brand analysis

Infanrix & Infanrix HeXa

Pediarix

Hexavac & Pentacel

Pneumococcal vaccines

Brand market share and sales

Brand analysis

Prevnar

Pneumovax 23

Meningococcal vaccines

Brand market share and sales

Other pediatric vaccines

Brand market share and sales

Brand analysis

Varivax

Comvax

Chapter 4 Adult vaccines

Summary

Introduction

Adult vaccine population

Adolescent vaccination

Elderly vaccination

Traveler vaccination

Hepatitis vaccines

Brand market share and sales

Brand analysis

Engerix-B

Recombivax HB

Twinrix

Havrix

Influenza vaccines

Brand market share and sales

Brand analysis

Fluzone

Fluvirin

FluMist

Other adult vaccines

Brand market share and sales

Chapter 5 Key players in the vaccine market

Summary

Introduction

Merck & Co.

Therapeutic focus

Marketed vaccines portfolio

R&D pipeline

ProQuad

HPV (human papilloma-virus) vaccine

Zoster vaccine

Rotateq

Wyeth

Therapeutic focus

Marketed vaccines portfolio

R&D pipeline

GSK

Therapeutic focus

Marketed vaccines portfolio

R&D pipeline

Boostrix

Priorix-Tetra

Rotarix

Conjugated meningitis A/C vaccine

Cervarix

Streptorix

Simplirix

Sanofi-Aventis

Therapeutic focus

Marketed vaccines portfolio

R&D pipeline

Menactra

Adacel

Chiron

Therapeutic focus

Marketed vaccines portfolio

R&D pipeline

MeNZB

ACYW meningococcal vaccine

Index

List of Figures

Figure 1.1: Timeline of vaccine development

Figure 2.2: Comparison of US/5EU IMS sales figures and global company-reported sales figures, 2003

Figure 3.3: Pediatric vaccination schedule for the US and 5 major European markets, 2004

Figure 3.4: Percentage of target population vaccinated the US, 5EU and global, 2003

Figure 3.5: Pediatric target population, 2005

Figure 3.6: MMR II SWOT analysis

Figure 3.7: Priorix SWOT analysis

Figure 3.8: Infanrix & Infanrix HeXa SWOT analysis

Figure 3.9: Pediarix SWOT analysis

Figure 3.10: Hexavac & Pentacel SWOT analysis

Figure 3.11: Prevnar SWOT analysis

Figure 3.12: Pneumovax 23 SWOT analysis

Figure 3.13: Varivax SWOT analysis

Figure 3.14: Comvax SWOT analysis

Figure 4.15: Adolescent population in the US and 5 major European markets, 2005

Figure 4.16: Elderly population in the US and 5 major European markets, 2005

Figure 4.17: Number of deaths from influenza and pneumonia in the US, 1995-2002

Figure 4.18: Engerix-B SWOT analysis

Figure 4.19: Recombivax HB SWOT analysis

Figure 4.20: Twinrix SWOT analysis

Figure 4.21: Havrix SWOT analysis

Figure 4.22: Fluzone SWOT analysis

Figure 4.23: Fluvirin SWOT analysis

Figure 4.24: FluMist SWOT analysis

Figure 5.25: Comparison of US/5EU IMS sales figures and global company-reported sales figures, 2003

Figure 5.26: Merck & Co s global therapeutic focus, 2003 & 2010

Figure 5.27: Wyeth s global therapeutic focus, 2003 & 2010

Figure 5.28: GSK s global therapeutic focus, 2003 & 2010

Figure 5.29: Sanofi-Aventis  global therapeutic focus, 2003 & 2010

Figure 5.30: Chiron s global therapeutic focus, 2003 & 2010

List of Tables

Table 2.1: Share of vaccines segment in anti-infectives market, US/Europe, 2002-2003

Table 2.2: Sales of vaccine products by indication and country ($m), 2002-03

Table 2.3: Top 10 vaccines in US/Europe by sales ($m), 2002-03

Table 3.4: US/European sales of MMR vaccines ($m), 2002-03

Table 3.5: US/European sales of combination vaccines with a tetanus component ($m), 2002-

Table 3.6: US/European sales of pneumococcal vaccines ($m), 2002-03

Table 3.7: US/European sales of meningococcal vaccines ($m), 2002-03

Table 3.8: US/European sales of other pediatric vaccines ($m), 2002-03

Table 4.9: US/European sales of hepatitis vaccines ($m), 2002-03

Table 4.10: US/European sales of influenza vaccines ($m), 2002-03

Table 4.11: US/European sales of other adult vaccines ($m), 2002-03

Table 5.12: Merck s vaccines R&D pipeline and global sales forecasts, 2007 & 2010

Table 5.13: Global sales of Wyeth s marketed vaccines portfolio ($m), 2002-03

Table 5.14: Wyeth s vaccines R&D pipeline and global sales forecasts, 2007 & 2010

Table 5.15: Global sales of GSK s marketed vaccines portfolio ($m), 2002-03

Table 5.16: GSK s vaccines R&D pipeline and global sales forecasts, 2007 & 2010

Table 5.17: Global sales of Sanofi-Aventis  marketed vaccines portfolio ($m), 2002-03

Table 5.18: Sanofi-Aventis  vaccines R&D pipeline and global sales forecasts, 2007 & 2010

Table 5.19: Sales of Chiron s marketed vaccines portfolio ($m), 2002-03

Table 5.20: Chiron s vaccines R&D pipeline and global sales forecasts, 2007 & 2010